36results about How to "Increase drug sensitivity" patented technology

Described herein is a network biology approach useful for the identification of multiple therapeutic targets, which can be targeted simultaneously using an agent (or a plurality of agents) to modulate cellular phenotypes, or in combination with pharmaceutical compounds to improve drug sensitivity and/or reduce drug doses to maintain efficacy while minimizing side effects. The preferred approach disclosed herein relies on first identifying the mediators of a condition of interest, and second, selecting gene combinations that are in competing/parallel pathways as targets for combination therapy.

The invention belongs to the technical field of genetic engineering, and discloses long noncoding RNA SNHG15 and application thereof in preparation of cancer diagnosis and treatment drugs. Cancers include colorectal cancer, breast cancer, kidney cancer and the like. Expression of the long noncoding RNA SNHG15 in tumor tissues of patients suffering from the colorectal cancer, the breast cancer andthe kidney cancer is up-regulated. The patients with highly-expressed long noncoding RNA SNHG15 have poor prognosis. Through expression knock-down of the long noncoding RNA SNHG15 in colorectal cancercell lines, invasion, migration and multiplication capabilities of cells can be inhibited, and drug susceptibility of colorectal cancer cell lines to antitumor drugs including gemcitabine and cis-platinum can be improved.

The invention relates to Nanodrug nanoparticles for realizing pH (Potential of Hydrogen) imaging of a tumor microenvironment, drug controlled release and cooperated chemotherapy effect on tumors. The Nanodrug nanoparticles are prepared through commonly coordinating a clinical commonly used chemotherapy drug Doxorubicin and a biological reduction drug (Banoxantrone) with bivalent copper ions through a self-assembling synthesis method. The Nanodrug nanoparticles provided by the invention can be used for intelligently adjusting a nano-scale according to different pH gradients of the tumor microenvironment and can effectively permeate tumor epithelial cells and express drug controlled release and cooperated anti-tumor activity under an aerobic/anoxic condition; the tumor anoxic tolerance of the drugs is solved and the potential toxic and side effects caused by the anthracycine chemotherapy drugs on patients is reduced.

Described herein are methods for diagnosing ovarian cancer. In particular, certain microRNAs are useful to the response to chemotherapy of ovarian cancer patients.

The invention provides an adhesive protein sourced from Bifidobacterium longum. An amino acid sequence of the protein is determined, on the basis, an expression strain of the protein is obtained with a genetic engineering technology, innovative design is performed in the aspects of induction expression, purification by chromatography, ultrafiltration concentration and the like aiming at characteristics of the strain and the adhesive protein, and an efficient preparation method of the adhesive protein is obtained. Furthermore, experiments find that the adhesive protein not only can adhere to an enterocyte, but also has a function of improving antibiotics sensibility of microorganisms, on the basis of the beneficial discovery, an application of the protein as an anti-bacterial synergist for antibiotics is determined, an application range of the protein is extended, and a new path for improving the drug sensitivity of the microorganisms is provided. Prominent technological effects are obtained on the basis of strict experimental measures, and broad application prospect is provided.

The invention belongs to the field of biotechnologies, and relates to a gene vaccine capable of inhibiting cancer cell growth. The gene vaccine can express a cell membrane surface protein metadherin (MTDH) and thus being named as a MTDH gene vaccine. The MTDH gene vaccine is utilized for immunization in an oral way. The MTDH gene vaccine can activate an immune response of CD8+ cytotoxic T cells on breast cancer cells 4T1 expressing MTDH antigens. The MTDH gene vaccine can inhibit breast cancer cell growth and pulmonary metastasis. Through being combined with adriamycin, the MTDH gene vaccine can improve adriamycin effects of inhibiting breast cancer cell growth and pulmonary metastasis, and prolong a life of a mouse loaded with cancer. More significantly, the MTDH gene vaccine does not produce obvious damages on main organs of a human body. Therefore, the MTDH gene vaccine provides a novel approach for improvement of the existing breast cancer treatment method.

The invention provides an adhesive protein sourced from Bifidobacterium longum. An amino acid sequence of the protein is determined, on the basis, experiments find that the adhesive protein not only can adhere to an enterocyte, but also has a function of improving antibiotics sensibility of microorganisms, and the antibiotics synergy on Salmonella typhimurium is particularly prominent. On the basis of the beneficial discovery, an application of the protein as an anti-bacterial synergist for Salmonella typhimurium is determined, an application range of the protein is extended, and a new path for improving the drug sensitivity of the microorganisms is provided. Prominent technological effects are obtained on the basis of strict experimental measures, and broad application prospect is provided.

The invention belongs to the technical field of biology, and especially relates to a Chinese herbal medicine micro-ecological preparation for subsidiarily preventing and treating pulmonary tuberculosis. The employed technical scheme is shown as follows: firstly preparing a kombucha mother solution and secondly preparing a Chinese herbal medicine extraction solution; inoculating a filtered Chinese herbal medicine extraction solution to the kombucha mother solution for fermentation, so as to use the fermentation solution to subsidiarily prevent and treat pulmonary tuberculosis; and additionally, performing low-temperature freeze drying on the completely-fermented Chinese herbal medicine micro-ecological preparation to form a bacterial powder of the Chinese herbal medicine micro-ecological preparation, and performing vacuum packaging for long-term storage. The product is capable of inhibiting growth and breeding of mycobacterium trberculosis through multiple action mechanisms. When for treatment, the product can be used in an oral administration way or in a spraying way. The product is non-toxic, can be used for subsidiary prevention, also can be used for subsidiary treatment, and can be used to treat pulmonary tuberculosis through both alimentary canal and respiratory tract. Therefore, the preparation has good comprehensive subsidiary prevention and treatment effects on pulmonary tuberculosis.

The invention relates to an application of solasodine to preparation of an antitumor drug sensitizer. According to the embodiment of the invention, the solamargine is used as a sensitizer of the antitumor drug for the first time, so that the drug sensitivity of tumor cells to the antitumor drug can be effectively improved, and the dosage of the antitumor drug can be reduced when the antitumor curative effect of the antitumor drug is remarkably improved. Reducing toxic and side effects of the antitumor drug on normal cells of a human body is facilitated. Therefore, according to the embodiment of the invention, the solasodine is used as the sensitizer of the antitumor drug, and has the advantages of high efficiency and low toxicity.

The invention discloses siRNA for targeted inhibition of SOS1 gene expression and application of the siRNA. The sequence of the siRNA is as follows: a sense strand is 5'-GCAGAATCTTCACCATCTA-3', and anantisense strand is 5'-TAGATGGTGAAGATTCTGC-3'. According to the SiRNA, by detecting the change of expression quantity of the mRNA level and protein level of SOS1, the effective siRNA sequence of SOS1, namely the SOS1-siRNA # 3 is screened out, the multiplication capacity and clonality of CML cells can be effectively inhibited, the growth of transplanted tumors can be effectively inhibited in animal bodies, and meanwhile, the drug sensitivity of the CML cells to imatinib is improved. Therefore, the SOS1 is a potential new target for treating chronic granulocytic leukemia, and the SOS1 siRNA has a potential value of overcoming the drug resistance of the imatinib.

The invention provides an extracellular regulatory protein kinase probe as shown in a formula I. A ring A on the structure can be covalently bound with 178 cysteine of an inactive site on the outer side of an ERK1/2 kinase structure in a specific targeting manner, and can effectively target ERK1/2; and the extracellular regulatory protein kinase probe does not inhibit the binding capacity of ERK1/2 and ATP and the kinase activity, but has targeting property on ERK1/2, so a small-molecule guiding group is provided for protein modification and marking research of targeted ERK kinase, the drug sensitivity of an inhibitor on extracellular regulatory protein kinase is improved, the probe is provided for an extracellular regulatory protein kinase inhibitor, and the extracellular regulatory protein kinase inhibitor is guided to act on the extracellular regulatory protein kinase site in a targeted manner so as to enable the inhibitor to play a role and to improve effect.

The invention provides an attachment protein derived from bifidobacterium longum, and discloses the amino acid sequence thereof; on the basis, experiments discover that the attachment protein not only can attach to enterocyte, but also has the function of improving microorganism antibiotic sensitivity, and especially for escherichia coli O157:H7, the antibiotic synergy is particularly prominent. Based on the beneficial discovery, the application of the protein as an anti-bacteria synergist, escherichia coli O157:H7, is determined, so that the application range of the protein is expanded, and at the same time, a new approach is provided for improving microorganism drug sensitivity. The prominent technological effect is achieved on the basis of strict experimental measures, and a broad application prospect is obtained.

The invention relates to a pharmaceutical composition for preventing and treating avian salmonellosis and a preparation method of the pharmaceutical composition. The pharmaceutical composition comprises the following components: artemisinic acid, ampicillin sodium, ciprofloxacin and polysaccharide and probiotic microcapsules. According to the pharmaceutical composition disclosed by the invention, monomer traditional Chinese medicine effective components are selected to be combined with the antibiotics, so that the use amount of traditional Chinese medicines and antibiotics can be reduced on the premise of improving the antibacterial inhibition and killing effects, and the bioavailability and efficacy of medicines are improved. Meanwhile, immune enhancement regulation is taken as an auxiliary treatment means, polysaccharide and probiotics are selected to regulate intestinal flora of the diseased chickens and reconstruct a good microbial system, so that the immune function of the chickens is enhanced, and the production performance is improved. The pharmaceutical composition disclosed by the invention can be administrated through mixed feeding, is suitable for clinical application, has an exact curative effect and is suitable for being applied to intensive large-scale farms.

The invention provides an application of mycobacterium tuberculosis protein Rv1508c to preparation of an antituberculotic drug sensitizer, and belongs to the technical field of biology. It is determined for the first time that the mycobacterium tuberculosis functional protein Rv1508c can improve sensitivity of mycobacterium tuberculosis to streptomycin, that is, the protein can promote a streptomycin drug to kill mycobacterium, and the protein can serve as a drug resistance reversal agent and a streptomycin sensitizer of an antituberculotic drug. New path and means can be provided for tuberculosis treatment by the mycobacterium tuberculosis functional protein Rv1508c as a new auxiliary component of the antituberculotic drug.

The invention provides attachment protein derived from bifidobacterium longum. The amino acid sequence of the protein is defined. On the basis, it is found through experiments that the attachment protein can be attached to enterocytes and has the effect of improving the sensitivity of microorganisms to the antibiotics, and the synergistic effect on the antibiotics is particularly outstanding especially for mononuclear Lister monocytogenes. Based on the beneficial discovery, application of the protein as an antibacterial synergist for the mononuclear Lister monocytogenes is confirmed, the application range of the protein is expanded accordingly, and meanwhile a new way for improving the drug sensitivity of the microorganisms is provided. An outstanding technical effect is achieved based on a strict experiment measure, and wide application prospects are achieved.

The invention relates to a PI3K and MTH1 targeting drug composition and applications thereof. The small-molecule targeting drug composition and a drug preparation provided by the invention comprise afirst preparation formed by a PI3K inhibitor or a pharmaceutically-acceptable carrier thereof, and a second preparation formed by a MTH1 inhibitor or a pharmaceutically-acceptable carrier thereof. Thecompatibility is reasonable. The combination of the two preparations can improve the drug sensitivity of the PI3K inhibitor, play the role of the MTH1 small-molecule inhibitor in the anti-tumor aspect and increase the treatment effect of the PI3K inhibitor. Experiments prove that: the combined administration of the PI3K inhibitor and the MTH1 inhibitor obviously enhances the tumor cell activity inhibition compared with the single administration, reduces the single administration dosage, can reduce the drug toxicity, is expected to become a new tumor treatment scheme aiming at the non-ideal treatment effect of the PI3K inhibitor, and has wide application prospect.